PHC2 promotes hepatocellular carcinoma progression and serves as a robust prognostic biomarker: A pancancer multiomics and clinical validation study
Cellular Signalling · 2026-08 · 144 · 112555
DOI: 10.1016/j.cellsig.2026.112555 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cellular Signalling, 2026-08. Verfasst von Qiang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Clinical Medical College, Southwest…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Biomarkers, Tumor. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Southwest Medical University.
Abstract (Originalsprache)
PURPOSE Polyhomeotic homolog 2 (PHC2) is a key component of Polycomb repressive complex 1, yet its clinical significance and biological function in hepatocellular carcinoma (HCC) remain unclear. This study aimed to elucidate the expression patterns, prognostic value, and oncogenic role of PHC2 in HCC progression. METHODS Multiomics datasets (e.g., TCGA, GTEx, and scRNA-seq) were analyzed to evaluate PHC2 expression and its correlation with the tumor microenvironment. Clinical validation was performed via immunohistochemistry using a tissue microarray (TMA) containing 94 HCC patient samples. The biological functions of PHC2 were investigated through in vitro assays (e.g., colony formation, wound healing, and Transwell) in HCC cell lines and an in vivo subcutaneous xenograft model. RESULTS Pancancer analysis revealed that PHC2 was significantly upregulated in HCC and correlated with poor prognoses across multiple malignancies, including brain lower grade glioma and adrenocortical carcinoma. Bioinformatic analyses suggested a potential correlation between PHC2 and macrophage infiltration. In the clinical TMA cohort, elevated PHC2 protein expression was significantly associated with advanced pathological stage and was identified as a robust independent risk factor for poor overall survival. Functionally, PHC2 knockdown markedly inhibited HCC cell proliferation, migration, and invasion in vitro. Conversely, PHC2 overexpression accelerated tumor growth in vivo, accompanied by the upregulation of proliferation markers Ki-67 and PCNA. CONCLUSIONS Our study identified PHC2 as a novel oncogenic driver that contributes to HCC progression and serves as a powerful independent prognostic biomarker. These findings highlight PHC2 as a promising therapeutic target, warranting further investigation into its dual role in tumor growth and microenvironment remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Clinical Medical College, Southwest Medical University, Luzhou, Sichuan, China. Electronic address: wq2k2…
- Department of Hepatobiliary Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Clinical Medical College, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Hepatobiliary Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Förderung
- Southwest Medical University
Zitieren
APA
Wang, Q., Ye, Y., Qin, S., Luo, M., Yang, J., & Zhang, M. (2026). PHC2 promotes hepatocellular carcinoma progression and serves as a robust prognostic biomarker: A pancancer multiomics and clinical validation study. Cellular Signalling, 144, 112555. https://doi.org/10.1016/j.cellsig.2026.112555
Vancouver
Wang Q, Ye Y, Qin S, Luo M, Yang J, Zhang M. PHC2 promotes hepatocellular carcinoma progression and serves as a robust prognostic biomarker: A pancancer multiomics and clinical validation study. Cellular Signalling. 2026;144:112555. doi:10.1016/j.cellsig.2026.112555
BibTeX
@article{Wang2026,
author = {Wang, Qiang and Ye, Yuntao and Qin, Shu and Luo, Ming and Yang, Jin and Zhang, Mengyu},
title = {PHC2 promotes hepatocellular carcinoma progression and serves as a robust prognostic biomarker: A pancancer multiomics and clinical validation study},
journal = {Cellular Signalling},
year = {2026},
volume = {144},
pages = {112555},
doi = {10.1016/j.cellsig.2026.112555}
}
EUVIMED